/
PBYI
$8.53-$0.19 (-2.13%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$459.4M
52M shares
52-week range
$4.30 – $9.40
83% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$1.61
PUMA BIOTECHNOLOGY INC
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
www.pumabiotechnology.com- Employees
- 179
- IPO / List date
- Mar 21, 2012
- HQ
- LOS ANGELES, CA
Held by traders on TradeandTell
No one on the platform currently holds PBYI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,942,413 | $12.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PBYI yet.
